Protein A Resin Market, By Product (Natural Protein A and Recombinant Protein A), By Matrix Type (Agarose-based, Glass or Silica Based, and Organic Polymer Based), By Application (Immunoprecipitation and Antibody Purification), By End User (Biopharmaceutical Companies, Clinical Research Laboratories, and Academic Institutes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2024

Code : CMI231

Pages :163

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

Protein A Resin Market Regional Insights

To learn more about this report, request sample copy

North America has established itself as the dominant region in the global protein A resin market. The region is expected to account for 39.2% of the market share in 2024. With major biopharmaceutical companies based in the U.S. and Canada, there is considerable demand for separation columns and purification resins like protein A used extensively in the production of monoclonal antibodies. The region accounts for over 40% of the worldwide biologics drug approvals, driving the need for large volumes of protein A resin used in downstream processing. Additionally, rapid approvals for biosimilars in recent years have further boosted the regional consumption. With a robust academia-industry linkage and focus on niche areas like cell and gene therapy, many novel biologics in the pipeline will require protein A resins during development and manufacture. This ensures the region's leadership position remains secure over the foreseeable future.

The Asia Pacific region has emerged as the fastest growing market for protein A resin globally. With China, India, South Korea, and other nations aggressively promoting biosimilars and developing their biopharmaceutical industries, the need for associated purification materials like protein A is rising sharply. Governments in Asia Pacific are also funding monoclonal antibody projects, helping establish local capabilities. For instance, China's 13th five-year plan allocated large grants toward advancing biologics production. This has attracted global resin suppliers to set up or expand their Asia Pacific sites, improving access. At the same time, contract manufacturers from the region are tapping overseas biopharma clients, leading to increased resin import. Along with the established Japanese market and its pursuits in advanced therapeutics, the Asia Pacific protein A resin landscape is poised for manyfold expansion in the coming years, driven by outpacing industry growth relative to other areas.